STAAR Surgical Co Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
STAAR Surgical Co (STAA) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $39.14 million for the 9-month period ending 2024-09-27, per its 10-Q filed 2024-10-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2024-10-30
- STAAR Surgical Co proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-09-27 was $11.94M, a 76.48% decline year-over-year.
- STAAR Surgical Co proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-06-28 was $5.82M, a 79.48% decline year-over-year.
- STAAR Surgical Co proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-03-29 was $21.39M, a 46.90% decline year-over-year.
- STAAR Surgical Co proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2023-12-29 was $25.49M.
- STAAR Surgical Co proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $144.85M, a 728.65% increase from fiscal 2022.
- STAAR Surgical Co proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2022 was $17.48M.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-09-27 | $11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $17.75M derived: sum of 2 quarters · filed 2024-10-30 | $39.14M 10-Q · filed 2024-10-30 | $64.63M derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-06-28 | $5.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $27.21M 10-Q · filed 2024-08-07 | $52.70M derived: sum of 3 quarters · filed 2024-08-07 | $103.43M derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-03-29 | $21.39M 10-Q · filed 2024-05-07 | $46.88M derived: sum of 2 quarters · filed 2024-05-07 | $97.61M derived: sum of 3 quarters · filed 2024-10-30 | $125.96M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-12-29 | $25.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $76.23M derived: sum of 2 quarters · filed 2024-10-30 | $104.57M derived: sum of 3 quarters · filed 2024-10-30 | $144.85M 10-K · filed 2024-02-27 |
| 2023-09-29 | $50.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $79.08M derived: sum of 2 quarters · filed 2024-10-30 | $119.36M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $28.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $68.62M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $40.28M 10-Q · filed 2024-05-07 | |||
| 2022-12-30 | $17.48M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| RxSight, Inc. (RXST) | United States | $0.197B | |
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |